106 related articles for article (PubMed ID: 22885620)
1. Preparation and antitumor activity of a polymeric derivative of methotrexate.
Zhou G; Cheng X; Wu S; Jiang X; Shi X; Chen J; Zhang J; Zhao J
Am J Med Sci; 2012 Oct; 344(4):294-9. PubMed ID: 22885620
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate esters of poly(ethylene oxide)-block-poly(2-hydroxyethyl-L-aspartamide). Part I: Effects of the level of methotrexate conjugation on the stability of micelles and on drug release.
Li Y; Kwon GS
Pharm Res; 2000 May; 17(5):607-11. PubMed ID: 10888314
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and toxicological properties of doxorubicin conjugated to [alpha],[beta]-poly[(2-hydroxyethyl)-L-aspartamide] administered intraperitoneally in mice.
Cheng C; Xue W; Diao H; Xia S; Zuo L; He A; Gao F; Huang Z; Chen J; Zhang J
Anticancer Drugs; 2010 Apr; 21(4):362-71. PubMed ID: 20468087
[TBL] [Abstract][Full Text] [Related]
4. Galactosylated α,β-poly[(2-hydroxyethyl)-L-aspartamide]-bound doxorubicin: improved antitumor activity against hepatocellular carcinoma with reduced hepatotoxicity.
Cheng X; Gao F; Xiang J; Jiang X; Chen J; Zhang J
Anticancer Drugs; 2011 Feb; 22(2):136-47. PubMed ID: 20966743
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacological evaluation and efficacy study of methotrexate-encapsulated polymer-coated layered double hydroxide nanoparticles for possible application in the treatment of osteosarcoma.
Ray S; Saha S; Sa B; Chakraborty J
Drug Deliv Transl Res; 2017 Apr; 7(2):259-275. PubMed ID: 28050892
[TBL] [Abstract][Full Text] [Related]
6. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
7. Self-aggregates of poly(2-hydroxyethyl aspartamide) copolymers loaded with methotrexate by physical and chemical entrapments.
Kang H; Kim JD; Han SH; Chang IS
J Control Release; 2002 May; 81(1-2):135-44. PubMed ID: 11992686
[TBL] [Abstract][Full Text] [Related]
8. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein.
Si M; Zhao J; Li X; Tian JG; Li YG; Li JM
Chin Med J (Engl); 2013 Nov; 126(21):4116-23. PubMed ID: 24229684
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and properties of a biodegradable polymer-drug conjugate: Methotrexate-poly(glycerol adipate).
Suksiriworapong J; Taresco V; Ivanov DP; Styliari ID; Sakchaisri K; Junyaprasert VB; Garnett MC
Colloids Surf B Biointerfaces; 2018 Jul; 167():115-125. PubMed ID: 29631222
[TBL] [Abstract][Full Text] [Related]
11. Intracellular delivery enhancement of poly(amino acid) drug carriers by oligoarginine conjugation.
Yang SR; Kim SB; Joe CO; Kim JD
J Biomed Mater Res A; 2008 Jul; 86(1):137-48. PubMed ID: 17957717
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates.
Ofner CM; Pica K; Bowman BJ; Chen CS
Int J Pharm; 2006 Feb; 308(1-2):90-9. PubMed ID: 16361072
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma.
Park J; Franco RS; Augsburger JJ; Banerjee RK
Curr Eye Res; 2007; 32(7-8):659-67. PubMed ID: 17852190
[TBL] [Abstract][Full Text] [Related]
14. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
15. In Vitro and In Vivo Efficacy of a Novel Glucose-Methotrexate Conjugate in Targeted Cancer Treatment.
Woźniak M; Pastuch-Gawołek G; Makuch S; Wiśniewski J; Krenács T; Hamar P; Gamian A; Szeja W; Szkudlarek D; Krawczyk M; Agrawal S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572433
[TBL] [Abstract][Full Text] [Related]
16. Effective removal of methotrexate by high-flux hemodialysis.
Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
[TBL] [Abstract][Full Text] [Related]
18. Understanding and managing methotrexate nephrotoxicity.
Widemann BC; Adamson PC
Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
[TBL] [Abstract][Full Text] [Related]
19. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
20. Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer.
Lobo ED; Balthasar JP
J Pharm Sci; 2005 Sep; 94(9):1957-64. PubMed ID: 16052545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
